111.64
Schlusskurs vom Vortag:
$111.40
Offen:
$111.64
24-Stunden-Volumen:
419.13K
Relative Volume:
0.21
Marktkapitalisierung:
$220.02B
Einnahmen:
$51.72B
Nettoeinkommen (Verlust:
$11.94B
KGV:
18.99
EPS:
5.88
Netto-Cashflow:
$13.81B
1W Leistung:
-0.45%
1M Leistung:
+2.36%
6M Leistung:
-3.45%
1J Leistung:
+15.40%
Novartis Ag Adr Stock (NVS) Company Profile
Vergleichen Sie NVS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NVS
Novartis Ag Adr
|
111.69 | 220.02B | 51.72B | 11.94B | 13.81B | 5.88 |
![]()
LLY
Lilly Eli Co
|
823.77 | 741.33B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
ABBV
Abbvie Inc
|
202.78 | 359.10B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
JNJ
Johnson Johnson
|
164.35 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
![]()
NVO
Novo Nordisk Adr
|
70.04 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
MRK
Merck Co Inc
|
89.62 | 223.02B | 64.17B | 17.12B | 18.10B | 6.73 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-13 | Herabstufung | UBS | Buy → Neutral |
2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-05-30 | Eingeleitet | Goldman | Buy |
2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-01-16 | Fortgesetzt | UBS | Buy |
2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
2022-12-05 | Hochstufung | Stifel | Hold → Buy |
2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2022-01-10 | Fortgesetzt | Citigroup | Buy |
2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
2021-03-10 | Herabstufung | Argus | Buy → Hold |
2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2020-09-10 | Hochstufung | UBS | Neutral → Buy |
2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
2019-04-25 | Hochstufung | Liberum | Hold → Buy |
2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-12-11 | Fortgesetzt | Jefferies | Buy |
2018-10-09 | Eingeleitet | Guggenheim | Neutral |
2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-01-25 | Bestätigt | Leerink Partners | Outperform |
2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
Why Pfizer Is My Largest Healthcare Position - The Motley Fool
5 Large Drug Stocks To Watch As Industry Recovers - Barchart
FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart
Novartis scraps use of diverse panels for hires in US - Reuters
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart
Giovanni Caforio, M.D. - Novartis
Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily
META_TITLE_QUOTE - Yahoo Finance
Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance
Novartis Gets CHMP Opinion For Label Expansion Of Fabhalta - Barchart
AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com
NVS Quantitative Stock Analysis - Nasdaq
Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha
Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart
Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK
Novartis 2017 Financial Results - Novartis
ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily
Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily
Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily
NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News
Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online
HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise
Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com
Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar
Novartis Financial Results – Q1 2021 - Novartis
Novartis Financial Results – Q2 2023 - Novartis
World Economic Forum Annual Meeting 2025 - Novartis
Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart
LGBTQI+ inclusion - Novartis
Novartis 2022 Financial Results - Novartis
Novartis at ASH - Novartis
Novartis 2021 Financial Results - Novartis
Novartis Financial Results – Q1 2023 - Novartis
Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa
J.P. Morgan Healthcare Conference 2024 - Novartis
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):